# McKesson: how the business works

> For learning only. Cityfort is not a registered investment adviser or broker-dealer and does not recommend buying or selling any security. Prices shown are dated and may be out of date.

McKesson Corporation · NYSE: MCK · Sector: Health Care

Updated for Q2 FY2027 · checked Nov 20, 2026

This is the plain-text version of https://cityfort.co/stocks/mckesson. Source ids in [brackets] refer to the list at the end. Credit: "Cityfort, McKesson: how the business works", with the page URL.

## The 30-second summary

McKesson distributes medicines and medical supplies to pharmacies, hospitals and doctors, mainly in the US and Canada, with FY2026 revenue of $403.4 billion. Almost all of that money goes back to drug makers: McKesson kept $1.18 of every $100 as net income. CVS Health alone was about 24% of FY2026 revenue, and the ten largest customers about 73%.

## 5 points

- **What it sells:** McKesson buys medicines from drug makers and delivers them to pharmacies, hospitals and clinics, and also sells specialty care, medical-surgical supplies and prescription technology services; FY2026 revenue was $403.4 billion. [S1]
- **Who pays it:** In FY2026, drug distribution customers in the US and Canada paid 83.4% of McKesson's revenue, specialist practices 12.0%, medical-surgical customers 2.9%, drug makers 1.4% and the sold Norway businesses 0.3%. [S1]
- **What it keeps from $100:** Of every $100 that came in during FY2026, McKesson kept $1.18 as net income, including a $480 million net gain on selling its Norway businesses; operating income was $6.2 billion. [S1]
- **Where the operating profit comes from:** North American Pharmaceutical brought 83.4% of FY2026 revenue but kept only 1.09% of it as segment profit, while Prescription Technology Solutions kept 17.98% on 1.4% of revenue. [S1]
- **The one thing to watch:** Borrowings rose from $6.5 billion at Mar 31, 2026 to $9.2 billion at Sep 30, 2026, while McKesson bought back about $3.4 billion of shares in the first half of FY2027. [S1, S14]

## What does McKesson sell?

McKesson buys medicines from drug makers and delivers them to pharmacies, hospitals and clinics in the US and Canada. It also sells cancer-care services, prescription software and medical-surgical supplies.

- **North American Pharmaceutical:** Delivers branded, generic, specialty and over-the-counter drugs to US and Canadian pharmacies and hospitals. The US business runs 27 distribution centers. [S1]
- **Oncology & Multispecialty:** Specialty drug distribution, group buying, infusion and practice services for cancer, eye and other specialist doctors. It supports The US Oncology Network of community cancer practices. [S1]
- **Prescription Technology Solutions:** Software and services that help patients get and afford medicines, such as electronic prior authorization (getting an insurer's approval before a prescription is filled) and patient enrollment for drug makers. [S1, S6]
- **Medical-Surgical Solutions:** Supplies and lab equipment for doctors' offices, surgery centers, nursing homes and home health agencies. It offers more than 270,000 national-brand products and over 4,000 of its own. [S1]

## Who pays McKesson?

- **Drugstore and mail-order chains:** National and regional chains, mail-order pharmacies and mass merchants buy drugs in bulk. CVS Health alone was about 24% of FY2026 revenue. [S1]
- **Independent pharmacies:** Community pharmacies buy drugs, generics programs and reimbursement help. About 3,900 of them belong to the Health Mart franchise. [S1]
- **Hospitals and health systems:** Hospitals, health systems and long-term care providers buy drugs, contracting help and pharmacy consulting. [S1]
- **Specialist doctors and cancer practices (12.0% of revenue):** They buy specialty drugs, group purchasing and practice services from the Oncology & Multispecialty segment, 12.0% of FY2026 revenue. [S1]
- **Drug makers (1.4% of revenue):** They pay Prescription Technology Solutions for prescription access and adherence services, 1.4% of FY2026 revenue. [S1]
- **Doctors' offices, surgery centers and nursing homes (2.9% of revenue):** They buy medical-surgical supplies from the Medical-Surgical Solutions segment, 2.9% of FY2026 revenue. [S1]
- **Customer concentration:** largest customer 24.0%, top 10 73.0% of revenue. In FY2026, CVS Health was about 24% of revenue and the ten largest customers, including group purchasing organizations, about 73%. The next two largest were 11% and 10%. The Q2 FY2027 10-Q gives no update. [S1]

## Where the money went (FY2026)

1. Customers paid McKesson $403.4 billion in FY2026, and other income added $236 million.
2. The medicines and supplies it resold cost $388.9 billion, leaving $14.6 billion of gross profit.
3. Operating costs took $8.3 billion, after a $480 million net gain on selling the Norway businesses. That left $6.2 billion of operating income.
4. Interest took $247 million and income tax $1.1 billion, leaving net income of $5.1 billion.
5. Partners in businesses McKesson controls but does not fully own took $337 million. McKesson kept $4.8 billion.

Sources: S1.

## Key numbers by year (US$ million)

Financials: consolidated, US$ million. Fiscal years are the company's own: Fiscal year ends Mar 31 (FY2026 = Apr 1, 2025 to Mar 31, 2026). — = not shown on the page.

| Year | Revenue | EBITDA | EBITDA margin | Net profit | Net margin | EPS (US$ per share, diluted) | Operating cash flow | Capital spending | Free cash flow | Sources |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| FY2022 | 263,966 | 2,798 | 1.1% | 1,114 | 0.4% | 7.23 | 4,434 | 388 | 4,046 | S5 |
| FY2023 | 276,711 | 4,989 | 1.8% | 3,560 | 1.3% | 25.03 | 5,159 | 390 | 4,769 | S4 |
| FY2024 | 308,951 | 4,544 | 1.5% | 3,002 | 1.0% | 22.39 | 4,314 | 431 | 3,883 | S3 |
| FY2025 | 359,051 | 5,058 | 1.4% | 3,295 | 0.9% | 25.72 | 6,085 | 537 | 5,548 | S2 |
| FY2026 | 403,430 | 6,941 | 1.7% | 4,762 | 1.2% | 38.38 | 6,155 | 436 | 5,719 | S1 |

- EBITDA here = operating income plus depreciation and amortization (from the cash flow statement).
- Net profit is the share belonging to the company's owners.

## Balance sheet (as of Sep 30, 2026, US$ million)

At Sep 30, 2026, McKesson's borrowings of $9.2 billion exceeded its cash by $2.7 billion (Cityfort calculation from Q2 FY2027 earnings release). That is about 0.4 years of FY2026 operating cash flow (Cityfort calculation from Q2 FY2027 earnings release and FY2026 10-K). Its equity is negative: a stockholders' deficit of $4.0 billion. [S14, S6, S1]

| Item | Value |
| --- | --- |
| Total debt | 9,208 |
| Cash and investments | 6,528 |
| Net debt (debt minus cash) | 2,680 |
| Net worth (shareholders' money) | −3,954 |
| Interest cover (times) | 25.1 |

- Borrowings exclude operating leases. They rose from $6.5 billion at Mar 31, 2026; at Sep 30, 2026 they included $3.2 billion of Medical-Surgical term loans (Cityfort calculation from Q2 FY2027 10-Q).
- Shares bought back and held in treasury had cost $32.0 billion by Mar 31, 2026.
- Opioid-related litigation liabilities were $5.7 billion at Mar 31, 2026 ($601 million due within a year), down from $6.4 billion a year earlier.
- The deficit leaves out the Apollo funds' convertible preferred stake in Medical-Surgical Solutions, which is shown as a redeemable noncontrolling interest.
- Interest coverage is FY2026 operating income of $6.2 billion divided by $247 million of interest expense (Cityfort calculation from FY2026 10-K).

## Who owns McKesson? (as of May 27, 2026)

McKesson has one class of common stock with one vote per share. The 17 directors and executive officers held 73,455 shares, under 1% of the 117,077,745 shares at May 27, 2026 (0.06%: Cityfort calculation from 2026 proxy statement). [S13, S6, S1]

- Officers and directors (as a group), shares: 0.06%

| Class | Shares (millions) | Votes per share | % of shares | % of votes | Traded | Sources |
| --- | --- | --- | --- | --- | --- | --- |
| Common stock (115,456,664 shares at Oct 30, 2026 (Q2 FY2027 10-Q cover), down from 120,204,051 at Apr 30, 2026.) | 115.46 | 1 | — | — | Yes | S6, S1 |

Holders of 5% or more (each row shows the date of its own filing):

| Holder | Shares | Votes | As of | Note | Sources |
| --- | --- | --- | --- | --- | --- |
| BlackRock, Inc. | 7.9% | — | Apr 14, 2025 | 9,207,960 shares, from a Schedule 13G/A filed Apr 14, 2025, as listed in the 2026 proxy. | S13 |
| Vanguard Capital Management LLC | 7.8% | — | Apr 30, 2026 | 9,180,981 shares, from a Schedule 13G filed Apr 30, 2026, as listed in the 2026 proxy. | S13 |

## What could go wrong

### A few customers buy most of the drugs

CVS Health was about 24% of FY2026 revenue and the ten largest customers about 73%. McKesson said on Nov 4, 2026 that it had agreed to extend the CVS partnership through June 2032. [S1, S14]

What to watch: Customer shares in the FY2027 10-K and any change to large distribution contracts.

### Opioid claims still open

Opioid-related litigation liabilities were $5.7 billion at Mar 31, 2026, and McKesson paid $512 million in FY2026. Some local governments did not join the settlement. An appeals court reopened the Cabell County and Huntington case on Oct 28, 2025. [S1]

What to watch: The opioid liability and payments in each 10-Q, and rulings in the cases left outside the settlement.

### The Medical-Surgical separation may change or slip

The FY2026 10-K describes the separation as a split-off, spin-off or both, intended to be tax-free. The 10-K warns it "may not be completed on the currently contemplated terms or timeline". Separation charges were $114 million in the first half of FY2027 ($87 million in the Medical-Surgical segment, $27 million in corporate), recorded in operating expenses. [S1, S6]

What to watch: A registration statement or completion date for Wellverse, and further separation charges.

### Very thin margins

McKesson kept $1.18 of net income per $100 of FY2026 revenue, so small cost or price changes move profit. Some drug-maker agreements pay McKesson more when manufacturers raise their prices. [S1]

What to watch: Gross profit per $100 of revenue and LIFO inventory adjustments in the next earnings releases.

### Customer bankruptcies

McKesson recorded a $725 million charge in FY2024 for its customer Rite Aid's bankruptcy, and a further $189 million bad-debt provision in the first half of FY2026. [S1, S6]

What to watch: Credit-loss provisions and receivables from large pharmacy customers.

### Cyber incident and data lawsuits

McKesson discovered a cybersecurity incident on Aug 25, 2026. Putative class actions filed since September 2026 allege it failed to protect patient data; no loss amount is disclosed. [S30, S6]

What to watch: Any update on the incident's impact and the class actions in later 10-Qs.

### More borrowing and a stockholders' deficit

Borrowings rose from $6.5 billion at Mar 31, 2026 to $9.2 billion at Sep 30, 2026. Buybacks of $4.75 billion in FY2026 and about $3.4 billion in the first half of FY2027 left a $4.0 billion stockholders' deficit. [S1, S14]

What to watch: Debt, cash and buyback amounts in each quarterly release.

## What to watch

Next: Q3 FY2027 results, Feb 4, 2027 (expected).

- **The Medical-Surgical separation:** McKesson named the planned standalone company Wellverse on Aug 5, 2026. The Q2 FY2027 10-Q gives no completion date, and the FY2026 10-K warns it may not be completed on the planned terms or timeline.
- **Borrowings and buybacks:** Borrowings were $9.2 billion at Sep 30, 2026, up from $6.5 billion at Mar 31, 2026. McKesson bought back about $3.4 billion of shares in the first half of FY2027, and $4.3 billion of authority remained.
- **The Option Care Health deal:** McKesson agreed in October 2026 to invest about $1.4 billion for about 49% of Option Care Health. McKesson said it expects the deal to close in the first half of calendar 2027, subject to approvals and a stockholder vote.
- **Adjusted EPS against the company's range:** Management said in the Nov 4, 2026 earnings release that it expects FY2027 adjusted EPS of $45.60 to $46.40. Adjusted EPS for the first six months was $21.59.

## Sources

- S1: McKesson Annual report FY2026 (year ended Mar 31, 2026). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/927653/000092765326000069/mck-20260331.htm (published May 8, 2026)
- S2: McKesson Annual report FY2025. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/927653/000092765325000036/mck-20250331.htm (published May 9, 2025)
- S3: McKesson Annual report FY2024. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/927653/000092765324000035/mck-20240331.htm (published May 8, 2024)
- S4: McKesson Annual report FY2023. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/927653/000092765323000038/mck-20230331.htm (published May 9, 2023)
- S5: McKesson Annual report FY2022. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/927653/000092765322000051/mck-20220331.htm (published May 9, 2022)
- S6: McKesson Quarterly report Q2 FY2027 (Sep 30, 2026). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/927653/000092765326000281/mck-20260930.htm (published Nov 4, 2026)
- S7: McKesson Quarterly report Q1 FY2027 (Jun 30, 2026). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/927653/000092765326000234/mck-20260630.htm (published Aug 5, 2026)
- S8: McKesson Quarterly report Q3 FY2026 (Dec 31, 2025). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/927653/000092765326000017/mck-20251231.htm (published Feb 4, 2026)
- S9: McKesson Quarterly report Q2 FY2026 (Sep 30, 2025). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/927653/000092765325000140/mck-20250930.htm (published Nov 6, 2025)
- S10: McKesson Quarterly report Q1 FY2026 (Jun 30, 2025). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/927653/000092765325000107/mck-20250630.htm (published Aug 6, 2025)
- S11: McKesson Quarterly report Q3 FY2025 (Dec 31, 2024). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/927653/000092765325000014/mck-20241231.htm (published Feb 6, 2025)
- S12: McKesson Quarterly report Q2 FY2025 (Sep 30, 2024). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/927653/000092765324000125/mck-20240930.htm (published Nov 7, 2024)
- S13: McKesson Proxy statement 2026 (DEF 14A). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/927653/000092765326000169/mck-20260612.htm (published Jun 12, 2026)
- S14: McKesson Earnings release Q2 FY2027 (8-K Ex. 99.1). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/927653/000092765326000279/mck_exhibit991x9302026.htm (published Nov 4, 2026)
- S15: McKesson Earnings release Q1 FY2027. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/927653/000092765326000232/mck_exhibit991x6302026.htm (published Aug 5, 2026)
- S16: McKesson Earnings release Q4 FY2026. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/927653/000092765326000066/mck_exhibit991x3312026.htm (published May 7, 2026)
- S17: McKesson Earnings release Q3 FY2026. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/927653/000092765326000015/mck_exhibit991x12312025.htm (published Feb 4, 2026)
- S18: McKesson Earnings release Q2 FY2026. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/927653/000092765325000138/mck_exhibit991x9302025.htm (published Nov 5, 2025)
- S19: McKesson Earnings release Q1 FY2026. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/927653/000092765325000105/mck_exhibit991x6302025.htm (published Aug 6, 2025)
- S20: McKesson Earnings release Q4 FY2025. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/927653/000092765325000034/mck_exhibit991x3312025.htm (published May 8, 2025)
- S21: McKesson Earnings release Q3 FY2025. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/927653/000092765325000010/mck_exhibit991x12312024.htm (published Feb 5, 2025)
- S22: McKesson Earnings release Q2 FY2025. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/927653/000092765324000121/mck_exhibit991x9302024.htm (published Nov 6, 2024)
- S23: McKesson Supplemental historical segment information (new segments). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/927653/000092765325000121/mck_ex991resegementation.htm (published Sep 18, 2025)
- S24: McKesson Investor Day press release. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/927653/000092765325000125/mck_ex991investordaypressr.htm (published Sep 23, 2025)
- S25: McKesson Press release: agreement to acquire Option Care Health with CD&R. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/927653/000092765326000253/ex991pressreleaseoctober62.htm (published Oct 6, 2026)
- S26: McKesson 8-K Item 1.01 Medical-Surgical credit agreement. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/927653/000092765326000045/mck-20260401.htm (published Apr 6, 2026)
- S27: McKesson 8-K Item 1.01 new $5.0B revolving credit facility. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/927653/000092765326000053/mck-20260428.htm (published Apr 28, 2026)
- S28: McKesson 8-K Item 1.01 Medical-Surgical term loan amendment. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/927653/000092765326000167/mck-20260609.htm (published Jun 12, 2026)
- S29: McKesson 8-K Item 5.02 officer departure (event Jun 29, 2026; signed Jul 1, 2026). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/927653/000092765326000185/mck-20260629.htm (published Jul 1, 2026)
- S30: McKesson 8-K Item 7.01. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/927653/000092765326000247/mck-20260825.htm (published Aug 28, 2026)
- S31: McKesson 8-K Item 5.02 news release. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/927653/000092765326000035/ex991-502newsreleaseissued.htm (published Mar 5, 2026)
- S32: McKesson SEC XBRL company facts (script output). SEC EDGAR. https://data.sec.gov/api/xbrl/companyfacts/CIK0000927653.json (published Nov 20, 2026)
- S33: McKesson 10-Q for Q1 FY2025. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/927653/000092765324000098/0000927653-24-000098-index.htm (published Aug 7, 2024)
- S34: McKesson 10-Q for Q3 FY2024. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/927653/000092765324000021/0000927653-24-000021-index.htm (published Feb 8, 2024)
